Physician profile
German Hernandez
NPI 1154367704
$1,312,385.41
in general payments reported to CMS, 2019-2025
59 companies · $125K in 2025
The $125K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $31K · 2021: $193K · 2022: $260K · 2023: $297K · 2024: $250K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $441K · Travel and Lodging: $86K · Honoraria: $81K · Consulting Fee: $40K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $800 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $441,386.50 |
| Travel and Lodging | $85,659.03 |
| Honoraria | $81,312.50 |
| Consulting Fee | $40,478.96 |
| Food and Beverage | $22,447.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $800.00 |
| Education | $423.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $303,215.14 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $217,245.14 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $164,317.95 | 2019-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $117,449.23 | 2019-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $102,513.62 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $87,054.77 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $69,043.73 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $67,932.10 | 2019-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $51,835.98 | 2019-2025 | Farxiga, Evusheld, Lokelma |
| Glaxosmithkline, LLC. | $48,996.33 | 2021-2025 | Benlysta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,081.20 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $19,026.06 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Lilly USA, LLC | $16,070.41 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,105.00 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $5,076.58 | 2019 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,317.19 | 2019-2025 | Tavneos, Krystexxa |
| Pfizer INC. | $1,509.88 | 2019-2024 | |
| Novo Nordisk As | $1,364.54 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $1,305.00 | 2022 | |
| Novo Nordisk INC | $782.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $747.94 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $629.93 | 2019-2025 | Rayaldee |
| Janssen Pharmaceuticals, INC | $469.08 | 2020 | |
| Horizon Therapeutics Plc | $348.04 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $286.83 | 2021-2024 | Acthar |
| Fresenius USA Marketing, INC. | $249.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $204.72 | 2020-2022 | |
| Genzyme Corporation | $179.91 | 2021-2023 | |
| Medtronic, INC. | $160.18 | 2025 | Ellipsys Vascular Access System |
| Cormedix INC. | $140.20 | 2024 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $107.88 | 2022-2025 | Livtencity |
| Inspire Medical Systems, INC. | $101.08 | 2023 | Inspire |
| Scpharmaceuticals INC. | $78.79 | 2025 | |
| Dexcom, INC. | $57.74 | 2023-2024 | Dexcom G6 Transmitter |
| Apellis Pharmaceuticals, INC. | $53.03 | 2025 | |
| Merck Sharp & Dohme LLC | $52.23 | 2024 | |
| Kyowa Kirin, INC. | $50.00 | 2025 | |
| Madrigal Pharmaceuticals | $30.37 | 2025 | Rezdiffra |
| Nxstage Medical, INC. | $29.14 | 2021 | |
| Pharmacosmos Therapeutics INC. | $26.72 | 2024 | Monoferric |
| Lexicon Pharmaceuticals, INC. | $26.14 | 2024 | |
| Daiichi Sankyo INC. | $22.86 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.08 | 2019 | |
| Abbott Laboratories | $17.35 | 2023 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $15.13 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $15.00 | 2024 | Gvoke Hypopen |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.